Substance / Medication

Brexucabtagene autoleucel

Overview

Active Ingredient
brexucabtagene autoleucel
RxNorm CUI
2387277

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement.
Muhsen Ibrahim N, Roloff Gregory W, Faramand Rawan et al. · Blood Adv · 2025
PMID: 40334068ObservationalFull text (PMC)
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Roloff Gregory W, Aldoss Ibrahim, Kopmar Noam E et al. · J Clin Oncol · 2025
PMID: 39418622ObservationalFull text (PMC)
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Aldoss Ibrahim, Roloff Gregory W, Faramand Rawan et al. · Blood Adv · 2024
PMID: 39093952ObservationalFull text (PMC)
Late-onset relapsing neurotoxicity after Brexucabtagene autoleucel associated with high chimeric antigen receptor T cells in cerebrospinal fluid.
De Philippis Chiara, Giacomel Arianna, Pensato Umberto et al. · Cytotherapy · 2025
PMID: 39152952Case Report
[Efficacy and toxicity of brexucabtagene autoleucel in the treatment of high-risk mantle cell lymphoma: description of a clinical case].
Novo Mattia, Savelli Corrado Benevolo, Botto Barbara et al. · Recenti Prog Med · 2025
PMID: 40084459Case Report
Unlocking Sanctuary Sites: The Efficacy of Brexucabtagene Autoleucel in Ocular B-ALL Relapse.
Calabretta Ludovica, Zappasodi Patrizia, Di Biase Carlo et al. · Am J Hematol · 2025
PMID: 39718764Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Brexucabtagene autoleucel (substance)
SNOMED CT
895363000
UMLS CUI
C5398046
RxNorm CUI
2387277

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.